SK76595A3 - Antacid composition and method of production - Google Patents

Antacid composition and method of production Download PDF

Info

Publication number
SK76595A3
SK76595A3 SK765-95A SK76595A SK76595A3 SK 76595 A3 SK76595 A3 SK 76595A3 SK 76595 A SK76595 A SK 76595A SK 76595 A3 SK76595 A3 SK 76595A3
Authority
SK
Slovakia
Prior art keywords
particles
antacid composition
antacid
aluminum
particle size
Prior art date
Application number
SK765-95A
Other languages
English (en)
Slovak (sk)
Inventor
Gary G Liversidge
Gregory L Mcintire
Original Assignee
Nanosystems Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanosystems Llc filed Critical Nanosystems Llc
Publication of SK76595A3 publication Critical patent/SK76595A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SK765-95A 1992-12-11 1993-12-03 Antacid composition and method of production SK76595A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98929692A 1992-12-11 1992-12-11
PCT/US1993/011720 WO1994013304A2 (en) 1992-12-11 1993-12-03 Antacid composition and method of production

Publications (1)

Publication Number Publication Date
SK76595A3 true SK76595A3 (en) 1997-01-08

Family

ID=25534976

Family Applications (1)

Application Number Title Priority Date Filing Date
SK765-95A SK76595A3 (en) 1992-12-11 1993-12-03 Antacid composition and method of production

Country Status (10)

Country Link
EP (1) EP0673253A1 (ko)
JP (1) JPH08504442A (ko)
KR (1) KR950703982A (ko)
AU (1) AU6390894A (ko)
CA (1) CA2150383A1 (ko)
CZ (1) CZ148695A3 (ko)
FI (1) FI952859A0 (ko)
NO (1) NO952261D0 (ko)
SK (1) SK76595A3 (ko)
WO (1) WO1994013304A2 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0714240B1 (en) * 1993-08-24 1998-09-23 Kappa Pharmaceuticals Limited Reduced absorption of fatty acids
ATE381624T1 (de) 1994-05-09 2008-01-15 Oxford Biomedica Ltd Retrovirale vektoren mit verminderter rekombinationsrate
US5874112A (en) * 1997-03-31 1999-02-23 Mcneil Ppc-Inc. Translucent antacid suspension
AU2002951438A0 (en) * 2002-09-17 2002-10-03 Nauveau Technology Investments Ltd Methods and compositions for treatment of excess stomach acid in mammals
RU2013148719A (ru) * 2013-10-31 2015-05-10 Геннадий Гильфанович Галимов Композиция на основе гидроксоалюмината хлорида магния, содержащая гидроксид магния, в качестве терапевтического препарата
WO2016104367A1 (ja) * 2014-12-22 2016-06-30 株式会社Ｌｔｔバイオファーマ 機能性ディスペプシア治療薬

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843778A (en) * 1970-04-28 1974-10-22 Rorer Inc William H Antacids
US4271142A (en) * 1979-06-18 1981-06-02 Life Savers, Inc. Portable liquid antacids
FR2512344A1 (fr) * 1981-09-08 1983-03-11 Af Aplicaciones Far Lab Procede de fabrication d'une suspension stable d'hydroxyde d'alumine et/ou d'hydroxyde de magnesie comme agent actif des antacida

Also Published As

Publication number Publication date
AU6390894A (en) 1994-07-04
NO952261L (no) 1995-06-08
WO1994013304A2 (en) 1994-06-23
FI952859A (fi) 1995-06-09
FI952859A0 (fi) 1995-06-09
EP0673253A1 (en) 1995-09-27
CA2150383A1 (en) 1994-06-23
JPH08504442A (ja) 1996-05-14
NO952261D0 (no) 1995-06-08
WO1994013304A3 (en) 1994-09-01
CZ148695A3 (en) 1995-12-13
KR950703982A (ko) 1995-11-17

Similar Documents

Publication Publication Date Title
RU2186562C2 (ru) Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления
JP4709873B2 (ja) ナノ粒子組成物
JP2022010290A (ja) 粘液浸透性被覆粒子、組成物、医薬組成物、医薬製剤、及びそれらの形成方法
AU2014232508B2 (en) Abiraterone acetate formulation
HUT65758A (en) Nanogranules containing surface modifier and cloud point modifier and process for production of them
DK2421540T3 (en) Hitherto unknown formulation with meloxicam
HU228097B1 (en) Pharmaceutical nanosuspension for medicament administration as systems with increased saturation solubility and speed of dissolution
JP2010047579A (ja) セルロース系表面安定剤を用いたヒト免疫不全ウイルス（ｈｉｖ）プロテアーゼ阻害剤のナノ結晶製剤及びそのような製剤の製造方法
JPH06211647A (ja) ナノ粒子を含む組成物及びその製造方法
JPH06227968A (ja) ナノ粒子を含む組成物及びその製造方法
CA2631492A1 (en) Processes for making particle-based pharmaceutical formulations for oral administration
NO303668B1 (no) Overflatemodifiserte legemiddel-nanopartikler, fremgangsmÕte for deres fremstilling samt dispersjon inneholdende slike partikler
CA2206430A1 (en) Sugar base surfactant for nanocrystals
JP2009519973A (ja) 粒子ベースの非経口投与用製薬剤形の製造方法
TW200927124A (en) Revaprazan-containing solid dispersion and process for the preparation thereof
CA2660647C (en) A suspension comprising benzimidazole carbamate and a polysorbate
CN109331184A (zh) 一种荷正电药物纳米结晶制剂及其制备方法
EP1658052B1 (en) Particle size reduction of bioactive compounds
SK76595A3 (en) Antacid composition and method of production
CN112451483B (zh) 一种棕榈酸帕利哌酮混悬液的制备方法
HUT72052A (en) Antacid compositions and methods of production
Santhosh et al. An Overview of Preparation, Characterization, and Application of Aquasomes
US20230310442A1 (en) Poly hydroxy oligomer coated dolutegravir aquasomes and method thereof
Magi et al. Organic solvent-free Benznidazole nanosuspension as an approach to a novel pediatric formulation for Chagas disease
Dey et al. Formulation and Evaluation of Gliclazide Loaded Controlled Release Microspheres